WADA Prohibited List raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
== Selected articles == Ionescu‐Zanetti, C., Mechler, A., Carter, S. A., & Lal, R. (2004). Semiconductive polymer blends: Correlating structure with transport properties at the nanoscale. Advanced Materials, 16(5), 385–389. Thimm, J., Mechler, A., Lin, H., Rhee, S., & Lal, R. (2005). Calcium-dependent open/closed conformations and interfacial energy maps of reconstituted hemichannels. Journal of Biological Chemistry, 280(11), 10646–10654. Mechler, A., Praporski, S., Atmuri, K., Boland, M., Separovic, F., & Martin, L. L. (2007). Specific and selective peptide-membrane interactions revealed using quartz crystal microbalance. Biophysical Journal, 93(11), 3907–3916. Del Borgo, M. P., Mechler, A. I., Traore, D., Forsyth, C., Wilce, J. A., Wilce, M. C., ... & Perlmutter, P. (2013). Supramolecular self-assembly of N-acetyl-capped β-peptides leads to nano-to macroscale fiber formation. Angewandte Chemie International Edition, 52(32). Hasan, I. Y., & Mechler, A. (2017). Nanoviscosity measurements revealing domain formation in biomimetic membranes. Analytical chemistry, 89(3), 1855–1862. West, N. G., Bamford, S. E., Pigram, P. J., Pan, J., Qi, D. C., & Mechler, A. (2023). Controllable hierarchical self-assembly: systematic study forming metallosupramolecular frameworks on the basis of helical beta-oligoamides. Materials Horizons, 10(12), 5584–5596.
== Open access type == According to its website, SCIRP publishes fee-based open-access journals (Gold OA). Payments are incurred per article published. Authors are permitted to archive their work (Green OA). Preprint, postprint, and the publisher's PDF version may be used. According to the society's website, journals published are fully open access, with reuse rights based on CC BY or CC BY-NC.
== Romería de Torrijos festival == On the second Sunday of October there is a public holiday in the town, called "Romería de Torrijos". In 1923, the decision was taken to establish a pilgrimage to the sanctuary of Torrijos on the second Sunday of October, carrying in procession the image of the patroness. The Virgin is accompanied by numerous pilgrims in decorated carriages or on horseback. When the Virgin arrives at the Torrijos Hacienda, mass is celebrated in the central courtyard. It is a major pilgrimage of the Aljarafe comarca.
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in approximately 100 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries. Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2024, it conducted more than 5,930 clinical trials involving over 1 million subjects, as well as over 500 studies for medical device companies. The company is one of the largest participants in the international primate trade and is engaged in animal testing, most specifically animal testing on non-human primates. The company traces its roots to Environmental Sciences Corporation, formed in 1968. It was known as Hazleton from 1972 to 1990, Corning Lab Services from 1990 to 1996, Covance from 1996 to 2021, and Labcorp Drug Development from 2021 to 2023. The company is ranked 992nd on the Fortune 1000 (76th in the healthcare sector).
Sources: en.wikipedia.org
passivation The process of coating a substance with a thin layer of a protective material, often a metal oxide, to create a shield against corrosion or other chemical reactions with the environment, thereby rendering the coated substance "passive" or less susceptible to undesirable reactions.
As enzyme-catalysed reactions are saturable, their rate of catalysis does not show a linear response to increasing substrate. If the initial rate of the reaction is measured over a range of substrate concentrations (denoted as [S]), the initial reaction rate (
After the internal structure of the atom was probed, amateur Dutch physicist Antonius van den Broek proposed in 1913 that the nuclear charge determined the placement of elements in the periodic table. The New Zealand physicist Ernest Rutherford coined the word "atomic number" for this nuclear charge. In van den Broek's published article he illustrated the first electronic periodic table showing the elements arranged according to the number of their electrons. Rutherford confirmed in his 1914 paper that Bohr had accepted the view of van den Broek. The same year, English physicist Henry Moseley using X-ray spectroscopy confirmed van den Broek's proposal experimentally. Moseley determined the value of the nuclear charge of each element from aluminium to gold and showed that Mendeleev's ordering actually places the elements in sequential order by nuclear charge. Nuclear charge is identical to proton count and determines the value of the atomic number (Z) of each element. Using atomic number gives a definitive, integer-based sequence for the elements. Moseley's research immediately resolved discrepancies between atomic weight and chemical properties; these were cases such as tellurium and iodine, where atomic number increases but atomic weight decreases. Although Moseley was soon killed in World War I, the Swedish physicist Manne Siegbahn continued his work up to uranium, and established that it was the element with the highest atomic number then known (92).
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.